Cladribine Thin-Film
-
BioNxt Receives European Patent Office “Intention to Grant” for Oral Cladribine Sublingual Film Targeting Patient-Friendly MS Therapies
BioNxt Solutions announced its German subsidiary received an “Intention to Grant” from the European Patent Office for a sublingual cladribine thin-film patent application (no. 23 729 446.7) targeting multiple sclerosis. Coupled with an EAPO “Readiness to Grant,” the filings could protect across 54 jurisdictions, reaching nearly 1 billion people. BioNxt is pursuing filings in the US, North America, and Japan, while advancing BNT23001 through bioequivalence studies and seeking partnerships, aiming for market entry in the growing oral MS treatment market.
